D. Gfeller

Discipline

Histoire, Philosophie et Sociologie des sciences (3)

Type de document

Articles (34) Recensions (3)

Co-auteur

Date

Source

Mot-clé

cancer (19) Cancer (19) Cancer (19) Human beings (17) Peptides (14) Molecules (14) Cells (14) Ligands (13) Immunotherapy (13) Properties (13) Immunotherapy (13) analyse (11) T cells (11) Analysis (11) Prophecies (10) protéine (9) Identification (9) Antigenic determinants (9) Proteins (9) Patients (9) Identification (9) Identification (9) Patients (9) Genes (8) Tumors (8) Mass spectrometry (8) Histocompatibility antigens (8) Forecasting (8) Tumors (8) spectacle (7)

Documents écrit par D. Gfeller (34) | parle de D. Gfeller (0)

Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.
J. Racle et al. (13 juin 2023)
Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.
H. Fritah et al. (21 avr. 2023)
Contemplating immunopeptidomes to better predict them.
D. Gfeller et al.
Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8(+ )T-cell epitopes.
D. Gfeller et al. (18 janv. 2023)
The MHC Motif Atlas: a database of MHC binding specificities and ligands.
D.M. Tadros et al. (6 janv. 2023)
Deciphering the landscape of phosphorylated HLA-II ligands.
M. Solleder et al. (20 mai 2022)
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
M. Arnaud et al.
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression.
D. Tavernari et al.
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting.
J. Schmidt et al. (16 févr. 2021)
Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients.
K. de Jonge et al. (2 févr. 2021)
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.
A. Cachot et al.
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4+ T cells.
B. Carreres et al.
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
B. Salomé et al. (26 nov. 2019)
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
A. Newey et al. (18 nov. 2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.
I. Siddiqui et al. (15 janv. 2019)
Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands.
MAS Perez et al. (2019)
Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival.
R.M. Pyke et al. (2019)
Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.
R. Mylonas et al.
The C-terminal extension landscape of naturally presented HLA-I ligands.
P. Guillaume et al. (15 mai 2018)
Polymorphic sites preferentially avoid co-evolving residues in MHC class I proteins.
L. Dib et al.
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
S. Bobisse et al. (15 mars 2018)
High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.
C. Chong et al.
Predicting Antigen Presentation-What Could We Learn From a Million Peptides?
D. Gfeller et al. (2018)
Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.
J. Racle et al. (13 nov. 2017)
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
S. Trabanelli et al. (19 sept. 2017)

next